Today, Zentalis Pharmaceuticals, Inc., a company specializing in pharmaceutical preparations, announced the results of its 2024 Annual Meeting of Stockholders. The meeting, which took place on June 21, 2024, saw high participation with approximately 93.09% of the outstanding common stock represented.
The stockholders voted on several key items during the meeting. The first item was the election of two Class I directors to serve on the company's board until the 2027 Annual Meeting of Stockholders. Dr. Kimberly Blackwell, currently serving as the Chief Executive Officer, received 48,055,584 votes in favor, with 12,810,370 votes withheld. Dr. Enoch Kariuki received 45,008,378 votes in favor, with 15,857,576 votes withheld. Both nominees were elected to the board.
In addition to the election of directors, the stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024. This proposal received overwhelming support with 66,098,083 votes in favor, 5,665 against, and 3,697 abstained.
The third proposal addressed the compensation of the company's named executive officers. This advisory vote, which is non-binding, resulted in 36,128,130 votes in favor, 24,729,730 against, and 8,094 abstentions.
The results of the meeting are based on the votes cast by the stockholders and reflect their collective input on the governance and oversight of Zentalis Pharmaceuticals. The company has filed the voting results with the Securities and Exchange Commission in a Form 8-K, which provides the official record of the meeting's outcomes.
This news is based on a press release statement from Zentalis Pharmaceuticals, Inc. and reflects the decisions made by its stockholders at the recent annual meeting.
In other recent news, Zentalis Pharmaceuticals has faced a series of significant developments. The company's drug candidate, Azenosertib, has been put under a partial clinical hold by the FDA due to reported deaths. This decision affected several studies, including trials for solid tumors and ovarian cancer.
Despite this setback, Jefferies downgraded Zentalis from Buy to Hold and adjusted the price target to $6.00, a significant drop from the previous target of $42.00. However, both Stifel and H.C. Wainwright maintained a Buy rating for the company, despite reducing their price targets due to concerns about ongoing clinical trials.
Zentalis also announced positive results from a Phase 1 trial evaluating a combination of Azenosertib and gemcitabine in patients with relapsed or refractory osteosarcoma. The results showed an 18-week event-free survival rate of 39%, supporting further evaluation of Azenosertib and gemcitabine in an upcoming Phase 2 trial.
Moreover, Zentalis has appointed Dr. Luke Walker to its Board of Directors, bringing his extensive experience in oncology and drug development. Lastly, the company has initiated a search for a new CFO following the departure of Melissa Epperly from her roles as Chief Financial Officer, Treasurer, Principal Financial (NASDAQ:PFG) Officer, and Principal Accounting Officer. These are the recent developments in the ongoing evolution of Zentalis Pharmaceuticals.
InvestingPro Insights
In light of Zentalis Pharmaceuticals' recent annual meeting, a look at the company's financial health and stock performance provides additional context for investors. According to InvestingPro data, Zentalis holds a market cap of $335.89 million, with a Price / Book ratio over the last twelve months as of Q1 2024 standing at 0.74. This suggests that the company's stock is trading below the value of its assets. Additionally, while the company's gross profit for the same period was $40.56 million, it reported a substantial operating loss, highlighting the challenges it faces in achieving profitability.
InvestingPro Tips indicate that Zentalis is in a position where it holds more cash than debt, which is a positive sign of financial stability. However, the company is not expected to be profitable this year, and its stock price has experienced significant volatility, with the price having fallen drastically over the last year. These factors may be of interest to investors who are considering the long-term potential of Zentalis, especially in light of the recent votes on governance and compensation at the stockholders' meeting.
For those looking to delve deeper into the financial metrics and strategic outlook for Zentalis Pharmaceuticals, InvestingPro offers additional insights. By using the coupon code PRONEWS24, investors can get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, unlocking a wealth of analysis and data points that could inform investment decisions. There are 12 more InvestingPro Tips available for Zentalis, which could further aid in evaluating the company's prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.